title: Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment.
abstract: Advancements in treatment of chronic myeloid leukemia (CML) turned this formerly fatal neoplasm into a manageable chronic condition. Therapy with tyrosine kinase inhibitors (TKIs) often leads to significant reduction of disease burden, known as the deep molecular response (DMR). Herein, we decided to analyze the cohort of CML patients treated in our center with TKIs, who obtain and retain DMR for a period longer than 24 months. The aim of the study was to evaluate the frequency of clonal cytogenetic aberrations in Philadelphia-negative (Ph-) cells in patients with DMR during TKI treatment. The analyzed data was obtained during routine molecular and cytogenetic treatment monitoring, using G-banded trypsin and Giemsa stain (GTG) karyotyping and reverse transcription quantitative PCR. We noticed that approximately 50% of patients (28 of 55) in DMR had, at some follow-up point, transient changes in the karyotype of their Ph- bone marrow cells. In 9.1% of cases (5 of 55), the presence of the same aberrations was observed at different time points. The most frequently appearing aberrations were monosomies of chromosomes 19, 20, 21, and Y. Statistical analysis suggests that the occurrence of such abnormalities in CML patients correlates with the TKI treatment time.
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland. Electronic address: michal.gniot@gmail.com.
authors.forename: Michał
authors.initials: M
authors.lastname: Gniot
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Lewandowski
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland.
authors.forename: Błażej
authors.initials: B
authors.lastname: Ratajczak
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland.
authors.forename: Maria
authors.initials: M
authors.lastname: Lewandowska
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland.
authors.forename: Agata
authors.initials: A
authors.lastname: Lehmann-Kopydłowska
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland; Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska, Poznan, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Jarmuż-Szymczak
authors.affiliation: Department of Hematology, University of Medical Sciences, Szamarzewskiego, Poznan, Poland.
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Komarnicki
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
keywords: CML; TKI treatment; cytogenetic abnormalities; deep molecular response